Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

Gruppo Italiano Studio Linfomi

Status: Completed

Conditions: Relapsed or Refractory Chronic Lymphoproliferative Disorders

Treatments: Drug: bendamustine +/- rituximab

Study type: Observational

Funder types: Other

Identifiers

NCT01224769

RETRO-BENDA

Details and patient eligibility

About

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

Enrollment: 109 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with relapsed or refractory chronic lymphoproliferative disorders
• salvage treatment with bendamustine +/- rituximab
• age ≥ 18 years

Exclusion criteria

• previous treatment with bendamustine

Trial design

109 participants in 1 patient group

bendamustine +/- rituximab

Treatment:

Drug: bendamustine +/- rituximab